28 March 2022
LungLife AI, Inc.
(the “Company” or “LungLife”)
LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces its maiden audited preliminary results for the year ended 31 December 2021, following admission to trading on AIM on 8 July 2021.
Summary and Highlights for the year:
Commenting, Paul Pagano, Chief Executive Officer of LungLife, said: “Since IPO, we have achieved several milestones which has kept us on track with our strategic vision. During the year, we laid the groundwork towards commencing our multi-centre validation study, and post-period end we enrolled our first participants. Our clinical laboratory in Thousand Oaks also achieved CAP accreditation in November 2021, confirming that we are maintaining the highest standards of excellence in laboratory testing for patients.
“Throughout the rest of the year we will continue with our validation study which we expect to complete in Q1 2023, as well as work towards regulatory authorisation and commercial reimbursement, which we made our first step towards post-period end when we were granted a CPT® PLA code. We remain focused on bringing early detection solutions to those who need them most, which will lead to better outcomes for people with lung cancer.”
1 Earnings before income tax, depreciation and amortisation, adjusted to exclude exceptional items and other operating income
Please click HERE to view the full announcement.